In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum β-lactamase [11]

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 1, 2007, Pages 187-188

  Shahid, M ^a   Singhai, M ^a   Malik, A ^a   Shukla, I ^a   Khan, H M ^a   Shujatullah, F ^a   Tahira, F ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Disc synergy; E. coli; ESBLs; Piperacillin tazobactam

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE CTX M15; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; TICARCILLIN; TIMENTIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME SYNTHESIS; ESCHERICHIA COLI; IN VITRO STUDY; INDIA; LETTER; LUNG LAVAGE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFTRIAXONE; DRUG COMBINATIONS; DRUG SYNERGISM; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; SULBACTAM;

EID: 34447555792     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm131     Document Type: Letter

References (6)

1. Frank U, Mutter J, Schmidt-Eisenlohr E et al. Comparative in vitro activity of piperacillin; piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Clin Microbiol Infect 2003; 9: 1128-32.
2. Bonnet R. Growing group of extended-spectrum β-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
3. Ensor VM, Shahid M, Evans JT et al. Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2006; 58: 1260-3.
4. Walsh TR, Toleman MA, Jones RN. Comment on: Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2007; 59: 799-800.
5. Gupta V, Dutta P, Agnihotri N et al. Comparative in vitro activities of seven new β-lactams, alone and in combination with β-lactamase inhibitors, against clinical isolates resistant to third generation cephalosporins. Braz J Infect Dis 2006; 10: 22-5.
6. Thomson KS. Controversies about extended-spectrum and AmpC β-lactamases. Emerg Infect Dis 2001; 7: 333-6.